Doxylamine/pyridoxine controlled-release - Duchesnay

Drug Profile

Doxylamine/pyridoxine controlled-release - Duchesnay

Alternative Names: Bonjesta; Diclectin; Diclegis; Doxylamine succinate/pyridoxine hydrochloride; Pyridoxine/doxylamine; Xonvea

Latest Information Update: 11 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Duchesnay Inc
  • Developer Alliance Pharma plc; Duchesnay Inc; Tzamal Medical
  • Class Antiemetics; Picolines; Pyridines; Small molecules; Vitamins
  • Mechanism of Action Biogenic monoamine uptake modulators; Histamine H1 receptor antagonists; Neurotransmitter stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Morning sickness
  • Phase III Hyperemesis gravidarum

Most Recent Events

  • 06 Jul 2018 Registered for Morning sickness in United Kingdom (PO)
  • 13 Jun 2018 Alliance Pharma plans to launch doxylamine/pyridoxine controlled release (Diclectin®) in Austria, Belgium, France, Germany, Italy, Luxembourg, Netherlands, Ireland and Switzerland in 2019
  • 08 Jun 2018 Alliance Pharma plans to launch doxylamine/pyridoxine controlled release in the UK in November 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top